BeiGene Q4 revenue $634M (+67% YoY); BRUKINSA sales $413M (+135%); operating loss narrows

BeOne Medicines Ltd.

2023-FY EPS reported -$0.65 revenue$2,458,779,000

Record total revenue $634M in Q4 (+67% YoY) and $2.5B full year (+74%); product revenue $630.5M (+86%).
BRUKINSA global sales $413M in Q4 (+135% YoY) and $1.3B full year (+129%); U.S. revenue $313M in Q4.
GAAP operating loss $383.8M in Q4, down 18% YoY; adjusted operating loss $267.2M, down 28%.
FDA approved BRUKINSA label update for PFS superiority in CLL; EU approved for R/R follicular lymphoma.
Advanced pipeline: sonrotoclax Phase 3 in CLL started; BTK CDAC BGB-16673 early data; TEVIMBRA CHMP positive opinion for NSCLC.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

BeOne Medicines Ltd. reported three months and year ended December 31, 2023 results: revenue $634.4 million and $2.5 billion.

Period: three months and year ended December 31, 2023
Revenue: $634.4 million and $2.5 billion
Result: reported results

Exact text from the filing

EX-99.1 (EX-99.1) --- BeiGene Reports Fourth Quarter and Full Year 2023 Financial Results and Business Updates • Continued rapid global growth with record total revenues of $634 million in fourth quarter and $2.5 billion in full-year 2023, increases of 67% and 74% from the prior-year periods • Strengthened leadership in hematology with global BRUKINSA®

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

BeOne Medicines Ltd. filing history →

Source: SEC EDGAR

accession 0001651308-24-000011

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.